Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Lymphoma, Non-Hodgkin (NHL). 39 results shown below.

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

[Complete title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 2398.00
Phase: II

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

[Complete title: A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma S/P Autologous Hematopoietic Cell Transplantation]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2620.00
Phase: II

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

[Complete title: A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 9023
Phase: II

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma

[Complete title: MK-3475 in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma]
Principal Investigator: Stephen Smith
Study Number: 9291
Phase: II

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

[Complete title: Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide]
Principal Investigator: Ajay Gopal, MD
Study Number: 9340
Phase: Pilot

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

[Complete title: A Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: C51101
Phase: II

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Ann Dahlberg
Study Number: 2010.00
Phase: II

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2206.00
Phase: II

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

[Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2241.00
Phase: II

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2546.00
Phase: II

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

[Complete title: A Phase II, Non-Randomized, Single Institution, Clinical Trial of Signal Transduction Inhibitors, Ibrutinib or Idelalisib, To Treat Patients with Persistent or relapsed B-cell Malignancies Following Allogeneic Hematopoietic Cell Transplantation.]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2561.00
Phase: II

Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)

[Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies]
Principal Investigator: Rachel Salit
Study Number: 2580.00
Phase: III

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

[Complete title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor]
Principal Investigator: David Maloney, MD, PhD
Study Number: 2639.00
Phase: I/II

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

[Complete title: A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction with Standard Chemotherapy for Treatment of Lymphoma in Patients with HIV Infection]
Principal Investigator: Hans-Peter Kiem, MD
Study Number: 2673.00
Phase: I

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

[Complete title: A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2728.00
Phase: I/II

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma

[Complete title: A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 9107
Phase: Pilot

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

[Complete title: Autologous Transplantation and Stem Cell-Based Gene Therapy with LVsh5/C46 (Cal-1), a Dual Anti-HIV Lentiviral Vector, for the Treatment of HIV-Associated Lymphoma]
Principal Investigator: Hans-Peter Kiem, MD
Study Number: 9183
Phase: I

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

[Complete title: A Window Study of Ixazomib in Untreated Indolent B-NHL]
Principal Investigator: Ajay Gopal, MD
Study Number: 9571
Phase: II

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

[Complete title: AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)]
Principal Investigator: Kasey Leger, MD
Study Number: AALL1231
Phase: III

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

[Complete title: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)]
Principal Investigator: Rebecca Gardner, MD
Study Number: AALL1331
Phase: III

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

[Complete title: ADVL1212, A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)]
Principal Investigator: Julie Park, MD
Study Number: ADVL1212
Phase: I

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

[Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab]
Principal Investigator: Julie Park, MD
Study Number: ADVL1412
Phase: I/II

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

[Complete title: ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)]
Principal Investigator: Rebecca Gardner, MD
Study Number: ANHL12P1

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

[Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)]
Principal Investigator: Ajay Gopal, MD
Study Number: 20110654
Phase: I

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

[Complete title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-cell Lymphomas]
Principal Investigator: Andrei Shustov, MD
Study Number: 20121207
Phase: III

A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

[Complete title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS 9973 in Subjects with Relapsed or Refractory Hematologic Malignancies]
Principal Investigator: Andrei Shustov, MD
Study Number: 20122094
Phase: II

A Long-term Extension Study of PCI-32765 (Ibrutinib)

[Complete title: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study]
Principal Investigator: Ajay Gopal, MD
Study Number: 20130268
Phase: III

Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL

[Complete title: A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20141037
Phase: II

Safety Study of SGN-CD70A in Cancer Patients

[Complete title: A Phase 1 trial of SGN-CD70A in patients with CD70-positive malignancies]
Principal Investigator: John Thompson, MD
Study Number: 20141105
Phase: I

ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies

[Complete title: A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects with B-cell Malignancies]
Principal Investigator: Stephen Smith
Study Number: 20142444
Phase: I/II

Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

[Complete title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma]
Principal Investigator: Michi Shinohara
Study Number: 20151086
Phase: III

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

[Complete title: An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma]
Principal Investigator: Stephen Smith
Study Number: 20151203
Phase: II

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

[Complete title: A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant.]
Principal Investigator: Stephen Smith
Study Number: 20151683
Phase: II

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) With Peripheral T-Cell Lymphoma (PTCL)

[Complete title: A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) PLUS Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20151824
Phase: I

A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)

[Complete title: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression CheckMate 436: CHECKpoint pathway and nivolumab clinical Trail Evaluation]
Principal Investigator: Andrei Shustov, MD
Study Number: 20152441
Phase: I/II

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

[Complete title: A phase 1, open-label, dose-esclation study of SGN-CD19B in patients with relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma]
Principal Investigator: Stephen Smith
Study Number: 20160030
Phase: I

A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma

[Complete title: A Phase 1b, Multicenter, Open-Label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma]
Principal Investigator: Stephen Smith
Study Number: 20160991
Phase: I

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)

[Complete title: A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies]
Principal Investigator: Damian Green, MD
Study Number: 9219
Phase: I/II

Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant

[Complete title: Phase 1/2 Study of CaspaCide T Cells from an HLA-Partially Matched Family Donor after Negative Selection of TCR aß+ T Cells in Pediatric Patients Affected by Hematological Disorders]
Principal Investigator: Ann Woolfrey, MD
Study Number: 9311
Phase: I/II

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials